Share on StockTwits

Greatbatch (NYSE:GB)‘s stock had its “neutral” rating restated by Zacks in a research report issued on Monday. They currently have a $48.00 price objective on the stock. Zacks‘s price target indicates a potential upside of 4.67% from the company’s current price.

Zacks’ analyst wrote, “Greatbatch’s 2014-second quarter earnings per share of $0.60 grew 7.1% y-o-y and met the Zacks Consensus Estimate. However, revenues of $172.1 million went up only 0.4% and missed the mark by 2.8%. We appreciate the company s effort to become a provider of complete medical devices system by heavy investment on R&D. Furthermore, the company’s product pipeline looks healthy. However, we are cognizant regarding softness in the smaller Electrochem division. The company also faces significant customer concentration risks. As such, we maintain our Neutral recommendation on the stock and set a target of $48.00.”

A number of other analysts have also recently weighed in on GB. Analysts at KeyCorp reiterated a “buy” rating on shares of Greatbatch in a research note on Friday, June 13th. They now have a $58.00 price target on the stock, up previously from $55.00. Analysts at Sterne Agee initiated coverage on shares of Greatbatch in a research note on Tuesday, June 3rd. They set a “buy” rating and a $53.00 price target on the stock.

Greatbatch (NYSE:GB) traded up 0.33% during mid-day trading on Monday, hitting $45.86. 211,330 shares of the company’s stock traded hands. Greatbatch has a 52 week low of $33.24 and a 52 week high of $51.64. The stock’s 50-day moving average is $48.10 and its 200-day moving average is $46.45. The company has a market cap of $1.142 billion and a price-to-earnings ratio of 24.50.

Greatbatch (NYSE:GB) last released its earnings data on Thursday, July 31st. The company reported $0.60 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.59 by $0.01. The company had revenue of $172.10 million for the quarter, compared to the consensus estimate of $177.06 million. During the same quarter last year, the company posted $0.56 earnings per share. Greatbatch’s revenue was up .5% compared to the same quarter last year. Analysts expect that Greatbatch will post $2.33 EPS for the current fiscal year.

Greatbatch, Inc (NYSE:GB) is developer and manufacturer of components for implantable medical devices (IMDs) and Electrochem batteries.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.